Results 191 to 200 of about 6,514,491 (295)

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Exploring Dietary Knowledge of People with Parkinson's Disease: Insights from Patient Focus Groups. [PDF]

J Restor Med
Thexton A, Mackay L, McClure C, Sodders E, Fiordalisi C, Zwickey H.   +5 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Barriers and Facilitators to Older Adults' Engagement in Social Prescribing: A Qualitative Study Using Focus Groups. [PDF]

J Clin Med
Sadio R, Henriques A, Nogueira P, Costa A.   +3 more
europepmc   +1 more source

Focus group [PDF]

, 2020
openaire   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

On the outside, looking in: A Focus Groups Study Exploring the Experience of Caring for a Loved One with Anhedonia

Shrewsbury L, Osei-Cobbina C, Agarwal S, Gogan S, Khan H, Cella M, Gumley A, Dunn BD, Edwards CJ.   +8 more
europepmc   +1 more source

Opportunities and barriers to engaging caregivers in firearm suicide prevention: findings from focus groups with caregivers of veterans. [PDF]

Inj Epidemiol
MacWilliams K, Marmion J, Blascyk D, Urbina S, Moyers R, True G.   +5 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Exploring the Acceptability and Suitability of Synchronous Online Focus Groups for Health Research With Métis Nation of Ontario Citizens: An Internet-Based Survey. [PDF]

JMIR Form Res
Simms AJ, Tsui N, Sadler R, Mersereau A, Rye C, Crenna CD, Evenson J, Edwards SA.   +7 more
europepmc   +1 more source